Nomogram-Integrated C-Reactive Protein/Albumin Ratio Predicts Efficacy And Prognosis In Patients With Thoracic Esophageal Squamous Cell Carcinoma Receiving Chemoradiotherapy

Objective To investigate the therapeutic effect and survival outcome using nomogram by incorporating significant inflammatory markers in patients with thoracic esophageal squamous cell carcinoma (ESCC) who received chemoradiotherapy (CRT) or single radiotherapy (RT). Method A total of 266 patients diagnosed with thoracic ESCC receiving standard curative RT only or concurrent CRT were retrospectively analysed. The patients were grouped for statistical analysis depending on the median values of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and C-reactive protein/albumin (CRP/Alb) ratio. The therapeutic effect was analysed by univariate and multivariate logistic analyses. The survival prognosis was estimated by univariate and multivariate Cox analyses. At last, the nomogram was developed by incorporating the significant inflammatory markers and clinicopathological parameters, and the predictive value was verified by calibration curve, concordance index (C-index) and decision curve. Results The treatment responses were highly associated with clinical stage, tumor location, NLR, PLR and CRP/Alb ratio (all P<0.05) by univariate logistic analysis. However, in the multivariate logistic analysis, the results showed that only CRP/Alb ratio (P=0.000) and TNM stage (P=0.008) were independent risk parameters for tumour response. In addition, NLR, PLR, CRP/Alb ratio, age and TNM stage were significantly associated with OS by the univariate Cox analysis (all P<0.05). Furthermore, the multivariate Cox analysis showed that only CRP/Alb ratio (P=0.000), TNM stage (P=0.000) and age (P=0.001) were considered independent prognostic factors for OS. Finally, the calibration curves of nomogram were highly consistent with actual observation for the therapeutic effect and prognosis, and the decision curve analysis showed more potential of clinical benefit of the nomogram compared with TNM staging system. Conclusion This research found that nomogram-integrated CRP/Alb ratio was promising as a predictive model for the therapeutic effect and survival outcome in patients with thoracic ESCC receiving CRT or single RT.

[1]  S. Ida,et al.  Prognostic significance of the modified Glasgow prognostic score in elderly patients with gastric cancer , 2013, Journal of Gastroenterology.

[2]  V. Baracos,et al.  Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer , 2011, British Journal of Cancer.

[3]  H. Ishwaran,et al.  Cancer of the esophagus and esophagogastric junction , 2010, Cancer.

[4]  T. Kawano,et al.  Correlation Between the Pretherapeutic Neutrophil to Lymphocyte Ratio and the Pathologic Response to Neoadjuvant Chemotherapy in Patients With Advanced Esophageal Cancer , 2012, World Journal of Surgery.

[5]  I. Endo,et al.  The Modified Glasgow Prognostic Score as a Predictor of Survival After Hepatectomy for Colorectal Liver Metastases , 2014, Annals of Surgical Oncology.

[6]  Dazhi Xu,et al.  Preoperative C-Reactive Protein/Albumin Ratio Predicts Prognosis of Patients after Curative Resection for Gastric Cancer , 2015, Translational oncology.

[7]  Wei Sun,et al.  Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: Neutrophil‐lymphocyte ratio and platelet‐lymphocyte ratio , 2016, Head & neck.

[8]  P. Kornprat,et al.  Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients , 2013, British Journal of Cancer.

[9]  D. Corley,et al.  Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. , 2001, International journal of epidemiology.

[10]  U. Langsenlehner,et al.  The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy. , 2015, European journal of cancer.

[11]  M. Maganti,et al.  Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer. , 2014, European journal of cancer.

[12]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[13]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[14]  Xiaozhong Chen,et al.  The C-reactive Protein/Albumin Ratio Is an independent Prognostic Factor for Overall Survival in Patients with Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiotherapy , 2016, Journal of Cancer.

[15]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[16]  M. Shinoda,et al.  A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907) , 2011, Annals of Surgical Oncology.

[17]  S. Franceschi,et al.  EPIDEMIOLOGY OF ESOPHAGEAL CANCER , 2013 .

[18]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[19]  T. Omori,et al.  Cumulative Prognostic Scores Based on Plasma Fibrinogen and Serum Albumin Levels in Esophageal Cancer Patients Treated with Transthoracic Esophagectomy: Comparison with the Glasgow Prognostic Score , 2014, Annals of Surgical Oncology.

[20]  I. Endo,et al.  Evaluation of the Glasgow Prognostic Score in patients receiving chemoradiotherapy for stage III and IV esophageal cancer. , 2016, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[21]  Baosheng Li,et al.  Sensitivity value of hematological markers in patients receiving chemoradiotherapy for esophageal squamous cell carcinoma , 2016, OncoTargets and therapy.

[22]  S. Shin,et al.  Pre-treatment neutrophil to lymphocyte ratio as a prognostic marker to predict chemotherapeutic response and survival outcomes in metastatic advanced gastric cancer , 2014, Gastric Cancer.

[23]  Yubo Liu,et al.  The prognostic value of the preoperative c-reactive protein/albumin ratio in ovarian cancer , 2017, BMC Cancer.

[24]  S. Natsugoe,et al.  Combined fibrinogen and neutrophil‐lymphocyte ratio as a prognostic marker of advanced esophageal squamous cell carcinoma , 2017, Cancer science.

[25]  Ying Huang,et al.  Preoperative platelet lymphocyte ratio (PLR) is superior to neutrophil lymphocyte ratio (NLR) as a predictive factor in patients with esophageal squamous cell carcinoma , 2014, World Journal of Surgical Oncology.

[26]  D. McMillan,et al.  The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer , 2012, British Journal of Cancer.

[27]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.